COSM: Cosmos Health projects >$22.7M annual U.S. revenue from four 18‑Series nutraceuticals (~75% gross margin)

AI Summary

Cosmos Health (COSM) said its U.S. 18 Series platform has launched five products and four with disclosed projections are targeted to generate over $22.7M in annualized U.S. revenue and roughly $17.0M in implied gross profit (based on ~75% gross margin). The program is at an early stage with encouraging direct‑to‑consumer demand and plans to scale to additional retail channels, but the figures are forward‑looking targets rather than reported results.

Positives

Company discloses >$22.7M projected annualized U.S. revenue across four 18‑Series products
Implied gross profit of ~ $17.0M based on company’s ~75% gross‑margin guidance
Management reports early DTC sales momentum and plans channel expansion to drive scale

Negatives

Revenue and gross‑profit figures are projections/targets, not realized results
18 Series is early stage (5 launched, targeting 18 total) with one launched product lacking a projection
Commercial upside depends on successful expansion beyond current direct‑to‑consumer channel